D3 Bio Showcases Breakthrough KRAS Research at 7th RAS-Targeted Therapies Summit

Shanghai, China – Sep 23, 2025– D3 Bio, a clinical-stage biotechnology company pioneering novel oncology therapeutics, presented compelling new research at the 7th RAS-Targeted Therapies Summit in Boston, Massachusetts, on September 16–18, 2025. D3 Bio delivered two highly regarded presentations that underscore major advances against KRAS G12C—a frequent oncogenic mutation found in non-small cell lung cancer, colorectal cancer, and pancreatic cancer.

Dr. Jing Zhang, Vice President and Head of Small Molecule Discovery, presented “The Discovery and Development of a New-Generation KRAS G12C Inhibitor, D3S-001.” She unveiled the unique mechanism of action behind one of D3 Bio’s novel KRAS G12C inhibitors. Her talk revealed that the critical factor in successfully targeting the GDP-bound form of KRAS lies in the kinetic speed of binding—a novel finding first reported by D3 Bio. By rapidly engaging the Switch II pocket before nucleotide exchange occurs, the molecule achieves robust and durable target inhibition. This distinct mechanism differentiates D3S-001 from other competitor compounds and underpins its strong cellular activity and in vivo efficacy across preclinical models.

Building on this mechanistic foundation, Dr. Cheng Chen, Senior Medical Director, presented “Phase I/II Study of D3S-001, a New-Generation KRAS G12C Inhibitor in Advanced/Metastatic Solid Tumors with KRAS G12C Mutations.” His presentation highlighted how this unique MOA translated into clinical benefit, with D3S-001 demonstrating:

• A favorable safety profile
• Promising efficacy across multiple tumor types
• Rapid and durable molecular responses
• Activity against resistance to first-generation KRAS G12C inhibitors
• Demonstrated CNS penetration
• Strong potential for immuno-oncology combinations

‍

“We are proud to present D3 Bio’s innovation and leadership on such a prestigious international stage within the RAS research community,” said Dr. George Chen, Founder, Chairman, and Chief Executive Officer. “These results highlight our commitment to addressing some of the toughest challenges in oncology and reinforce the transformative potential of our pipeline for patients with RAS-driven cancers.”

The RAS-Targeted Therapies Summit is a world’s leading industry-dedicated meeting focused on overcoming the challenges of targeting RAS mutations. The 2025 summit convened global leaders in drug discovery, translational science, and clinical development to accelerate breakthroughs against one of oncology’s most formidable drivers.

About D3 Bio

D3 Bio is a global biotechnology company focused on the discovery, development, and registration of new medicines in oncology and immunology. The company's discovery and development platforms leverage proprietary clinical insight and biomarker strategies to create novel and clinically meaningful therapies for patients in need. D3 Bio's oncology programs target driver mutations or critical immune pathways and are designed to have first-in-class or best-in-class potential. D3 Bio owns global rights for all of its programs.
For more information, please visit www.d3bio.com.

‍

Media Contact:
Rui Liu
Head, Corporate Affairs
‍bd@d3bio.com
Shanghai, China